Table of Contents

• Trial overview
• Patient groups and conditions
• Trial designs and phases
• Main outcomes being measured
• Special populations and care settings
• What the trials compare

Trial overview

The trial data show that Amoxicillin Sodium is being studied in several different clinical situations, mostly for infections.^[1] The studies are interventional, which means researchers assign treatments and compare results between groups.^[1] Most of the studies are in Phase 3, while a smaller number are in Phase 2 or low-intervention designs.^[1]

These trials do not focus on one single disease.^[1] Instead, they test Amoxicillin Sodium in bone and joint infections, urinary tract infection, skin infection, bloodstream infection, pneumonia, and severe infections in hospital or intensive care settings.^[1]

Patient groups and conditions

One important study includes patients with infection of osteosynthesis material, which means metal or other material used to hold a broken bone in place.^[1] These patients are treated after surgical cleaning of the infected area, with either the implant kept in place or removed.^[1]

Other trials include people with periprosthetic joint infection, which is an infection around an artificial joint such as a knee or hip replacement.^[1] Another study includes adults with lower-limb erysipelas, a skin infection, and another includes patients with febrile urinary tract infection, which means a urine infection with fever.^[1]

Some studies involve more serious hospital cases, such as uncomplicated enterococcal bacteremia, catheter-related bloodstream infection due to Staphylococcus aureus, severe COPD exacerbation, and serious infections in critically ill patients.^[1] There is also a study in children with systemic infections and another in pregnant women with premature rupture of membranes at term.^[1]

Trial designs and phases

Most Amoxicillin Sodium trials in the data are Phase 3 studies, which usually compare treatments in larger groups of patients.^[1] Examples include trials in osteosynthesis material infection, enterococcal bacteremia, erysipelas, community-acquired pneumonia, and catheter-related bloodstream infection.^[1]

There are also smaller or earlier studies.^[1] The urinary tract infection study is Phase 2, and the medication-related osteonecrosis of the jaw study is also Phase 2.^[1] Some studies are marked as low intervention, meaning the treatment strategy is being studied with less intense intervention than a standard drug trial.^[1]

The trials are usually randomized, open-label, or multicenter.^[1] Randomized means patients are assigned by chance to different treatment groups, and multicenter means the study is run in more than one hospital or clinic.^[1]

Main outcomes being measured

The studies measure different kinds of success depending on the infection being treated.^[1] In the osteosynthesis material trial, the main outcome is clinical failure, including return of symptoms, new signs of infection, need for extra antibiotics, and related surgical or culture findings.^[1]

In the urinary tract infection trial, the main outcome is clinical response, which includes no new healthcare visits or antibiotics, fever staying down, and symptoms improving at the test-of-cure visit.^[1] In the erysipelas trial, the main outcome is complete remission, meaning fever and local skin signs disappear and no extra antibiotics are needed.^[1]

Other studies use outcomes such as clinical success at test of cure, remission at a set week, vital status at day 28, cure without relapse at day 30, or the number of days alive without antibiotics.^[1] One trial in periprosthetic joint infection also focuses on cost-utility, which compares treatment costs with quality-adjusted life years, a measure that combines length and quality of life.^[1]

Special populations and care settings

Some Amoxicillin Sodium trials are built around special patient groups.^[1] These include critically ill children, elderly hospitalized patients with viral infection, adult haematology patients with chemotherapy-induced fever, and patients receiving CAR-T cell therapy for blood cancers.^[1]

Several studies also take place in intensive care units or other hospital settings where infection risk is high.^[1] In these settings, the studies may look at antibiotic exposure levels, days without antibiotics, or whether a shorter treatment plan is enough.^[1]

One trial in children studies early model-informed precision dosing, which means using early drug level information to help guide dosing so that treatment reaches the intended target.^[1] Another trial in critically ill patients measures whether antibiotic plasma targets are reached, which is a laboratory way to see if the drug level in blood matches the planned target.^[1]

What the trials compare

Many of the studies compare Amoxicillin Sodium with other antibiotics or with different treatment durations.^[1] For example, some trials compare a shorter course with a longer course, while others compare Amoxicillin Sodium-based treatment with another standard antibiotic plan.^[1]

In some trials, Amoxicillin Sodium is one option among several antibiotics listed in the protocol.^[1] In other trials, it appears as part of a broader treatment strategy being tested for infection control, recovery, or prevention of worsening disease.^[1]

Across the trial data, the main research goal is not to describe the drug itself, but to learn when Amoxicillin Sodium-based treatment works best, which patients may benefit, and whether shorter or alternative antibiotic strategies can give similar results.^[1]